Menu
Search
|

Menu

Close
X

Agenus Inc AGEN.OQ (NASDAQ Stock Exchange Capital Market)

2.08 USD
-0.11 (-5.02%)
As of 1:30 AM IST
chart
Previous Close 2.19
Open 2.21
Volume 205,051
3m Avg Volume 379,048
Today’s High 2.22
Today’s Low 2.05
52 Week High 6.19
52 Week Low 2.05
Shares Outstanding (mil) 87.00
Market Capitalization (mil) 409.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
43
FY16
23
FY15
25
EPS (USD)
FY18
-0.528
FY17
-1.220
FY16
-1.461
FY15
-1.152
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
9.95
5.73
Price to Book (MRQ)
vs sector
--
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.72
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
-75.39
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Garo Armen
Chairman of the Board, Chief Executive Officer, Founder, Since 1994
Salary: $575,000.00
Bonus: $485,000.00
Christine Klaskin
Principal Accounting Officer, Since 2018
Salary: $250,000.00
Bonus: $102,000.00
Karen Valentine
General Counsel, Chief Legal Officer, Since 2015
Salary: $340,000.00
Bonus: $210,000.00
Ozer Baysal
Chief Commercial Officer, Head of HR, Since 2017
Salary: $209,000.00
Bonus: $95,000.00
Christian Cortis
Chief Strategy Officer and Head of Finance, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3 Forbes Rd
LEXINGTON   MA   02421-7305

Phone: +1781.6744410

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

SPONSORED STORIES